Open Access

Journal of Molecular Medicine

, том 99 , издание 2 , страницы 303-310

An update to “novel therapeutic approaches for treatment of COVID-19”

Тип публикации: Journal Article

Дата публикации: 2021-01-03

Springer Nature

Journal of Molecular Medicine

scimago Q1

wos Q1

БС1

SJR: 1.473

CiteScore: 9.4

Impact factor: 4.2

ISSN: 09462716, 14321440

DOI: 10.1007/s00109-020-02027-1

Скопировать DOI

PubMed ID: 33392632

Drug Discovery

Molecular Medicine

Genetics (clinical)

Краткое описание

Although the exact mechanism of pathogenesis in COVID-19 is not fully understood, cytokine storm following viral infection plays an important role in the initiation and progression of disease. SARS-CoV-2 infection induces over-activation of the immune system andmassive production of inflammatory cytokines. Therefore, it is necessary to develop new strategies to modulate inflammatory responses [1]. Despite many efforts to improve therapeutic protocols for COVID-19, there is no specific approved treatment or preventable vaccine for this disease [2, 3]. However, intensive research has been conducted to both prevent and treat COVID-19. This commentary is an update for our recent paper in “Journal of Molecular Medicine, June 2020” and highlights the recent achievements in terms of preventive and therapeutic approaches in COVID-19 [4].

Найдено

2 цитирования

Кошелева Настасья

к.б.н., доц.

65 публикаций, 1 073 цитирования, 11 рецензий

Индекс Хирша: 18

Первый Московский государственный медицинский университет имени И. М. Сеченова

Научно-исследовательский институт общей патологии и патофизиологии

Области научных интересов

Биология развития

1 цитирование

Бикмулина Полина

30 публикаций, 528 цитирований

Индекс Хирша: 14

Первый Московский государственный медицинский университет имени И. М. Сеченова

Области научных интересов

3D bioprinting

3D культивирование клеток

Топ-30

Журналы

	1 2
Journal of Molecular Medicine	Journal of Molecular Medicine, 2, 11.11% Journal of Molecular Medicine 2 публикации, 11.11%
Vaccines	Vaccines, 2, 11.11% Vaccines 2 публикации, 11.11%
Drug Discovery Today	Drug Discovery Today, 1, 5.56% Drug Discovery Today 1 публикация, 5.56%
Bio-Design and Manufacturing	Bio-Design and Manufacturing, 1, 5.56% Bio-Design and Manufacturing 1 публикация, 5.56%
Cells	Cells, 1, 5.56% Cells 1 публикация, 5.56%
Antioxidants	Antioxidants, 1, 5.56% Antioxidants 1 публикация, 5.56%
Frontiers in Immunology	Frontiers in Immunology, 1, 5.56% Frontiers in Immunology 1 публикация, 5.56%
Frontiers in Cell and Developmental Biology	Frontiers in Cell and Developmental Biology, 1, 5.56% Frontiers in Cell and Developmental Biology 1 публикация, 5.56%
Human Cell	Human Cell, 1, 5.56% Human Cell 1 публикация, 5.56%
Value in Health	Value in Health, 1, 5.56% Value in Health 1 публикация, 5.56%
International Immunopharmacology	International Immunopharmacology, 1, 5.56% International Immunopharmacology 1 публикация, 5.56%
Biochimica et Biophysica Acta - General Subjects	Biochimica et Biophysica Acta - General Subjects, 1, 5.56% Biochimica et Biophysica Acta - General Subjects 1 публикация, 5.56%
Drug Development and Industrial Pharmacy	Drug Development and Industrial Pharmacy, 1, 5.56% Drug Development and Industrial Pharmacy 1 публикация, 5.56%
Journal of Clinical Psychopharmacology	Journal of Clinical Psychopharmacology, 1, 5.56% Journal of Clinical Psychopharmacology 1 публикация, 5.56%
Stem Cell Research and Therapy	Stem Cell Research and Therapy, 1, 5.56% Stem Cell Research and Therapy 1 публикация, 5.56%
GeroScience	GeroScience, 1, 5.56% GeroScience 1 публикация, 5.56%
	1 2

Издатели

	1 2 3 4 5 6
Springer Nature	Springer Nature, 6, 33.33% Springer Nature 6 публикаций, 33.33%
Elsevier	Elsevier, 4, 22.22% Elsevier 4 публикации, 22.22%
MDPI	MDPI, 4, 22.22% MDPI 4 публикации, 22.22%
Frontiers Media S.A.	Frontiers Media S.A., 2, 11.11% Frontiers Media S.A. 2 публикации, 11.11%
Taylor & Francis	Taylor & Francis, 1, 5.56% Taylor & Francis 1 публикация, 5.56%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 5.56% Ovid Technologies (Wolters Kluwer Health) 1 публикация, 5.56%
	1 2 3 4 5 6

Мы не учитываем публикации, у которых нет DOI.
Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.

Войти с ORCID

Метрики

Цитировать

ГОСТ |

Цитировать

ГОСТ Скопировать

Hossein‐Khannazer N. et al. An update to “novel therapeutic approaches for treatment of COVID-19” // Journal of Molecular Medicine. 2021. Vol. 99. No. 2. pp. 303-310.

ГОСТ со всеми авторами (до 50) Скопировать

Hossein‐Khannazer N., Shokoohian B., Shpichka A., Aghdaei H. A., Timashev P. S., Vosough M. An update to “novel therapeutic approaches for treatment of COVID-19” // Journal of Molecular Medicine. 2021. Vol. 99. No. 2. pp. 303-310.

RIS |

Цитировать

RIS Скопировать

TY - JOUR

DO - 10.1007/s00109-020-02027-1

UR - https://doi.org/10.1007/s00109-020-02027-1

TI - An update to “novel therapeutic approaches for treatment of COVID-19”

T2 - Journal of Molecular Medicine

AU - Hossein‐Khannazer, Nikoo

AU - Shokoohian, Bahare

AU - Shpichka, Anastasia

AU - Aghdaei, Hamid Asadzadeh

AU - Timashev, Petr S.

AU - Vosough, Massoud

PY - 2021

DA - 2021/01/03

PB - Springer Nature

SP - 303-310

IS - 2

VL - 99

PMID - 33392632

SN - 0946-2716

SN - 1432-1440

ER -

BibTex |

Цитировать

BibTex (до 50 авторов) Скопировать

@article{2021_Hossein‐Khannazer,

author = {Nikoo Hossein‐Khannazer and Bahare Shokoohian and Anastasia Shpichka and Hamid Asadzadeh Aghdaei and Petr S. Timashev and Massoud Vosough},

title = {An update to “novel therapeutic approaches for treatment of COVID-19”},

journal = {Journal of Molecular Medicine},

year = {2021},

volume = {99},

publisher = {Springer Nature},

month = {jan},

url = {https://doi.org/10.1007/s00109-020-02027-1},

number = {2},

pages = {303--310},

doi = {10.1007/s00109-020-02027-1}

}

MLA

Цитировать

MLA Скопировать

Hossein‐Khannazer, Nikoo, et al. “An update to “novel therapeutic approaches for treatment of COVID-19”.” Journal of Molecular Medicine, vol. 99, no. 2, Jan. 2021, pp. 303-310. https://doi.org/10.1007/s00109-020-02027-1.